Józef Drzewoski - Academia.edu (original) (raw)
Papers by Józef Drzewoski
Menopause Review/Przegląd Menopauzalny, May 11, 2009
Anaphylaxis is a severe, life-threatening systemic reaction of hypersensitivity occurring unexpec... more Anaphylaxis is a severe, life-threatening systemic reaction of hypersensitivity occurring unexpectedly in healthy individuals in response to an allergen. Anaphylactic shock combines anaphylaxis with coexisting hypotension. Aronia (Latin - Aronia melanocarpa, common name - black chokeberry) is a bush commonly grown in European countries. Its fruit is used in food industry for production of fruit products, including juices. Due to its antioxidative properties, aronia is recommended as a dietary supplement for people with arterial hypertension, diabetes and lipid metabolism disorders. We present a case of a 54 year old male patient with cardiovascular disease and type 2 diabetes, admitted with signs and symptoms of anaphylactic shock. The symptoms appeared directly after drinking aronia juice. Medical history revealed similar symptoms of alimentary hypersensitivity, requiring hospitalisation and intensive pharmacotherapy, occurred also following ingestion of highbush blueberries and raspberries. The presented case is the first case of anaphylactic shock following ingestion of aronia juice noted in the literature. Additionally, presence of some additional factors that could be responsible for development of hypersensitivity reaction is notable. It is suggested that the patient’s age, gender and presence of cardio-metabolic conditions, including type 2 diabetes, could play an important role.
PubMed, Nov 1, 2000
Obesity is one of the pathologies with ever-increasing prevalence in modern societies. Its occurr... more Obesity is one of the pathologies with ever-increasing prevalence in modern societies. Its occurrence is strongly associated with increased risk of developing diabetes mellitus, atherosclerosis, hypertension, stroke, heart and respiratory failure, breast, prostate and gut cancer, gall stones, arthropathy. Obesity is common in Polish population. Obesity treatment is difficult and frustrating. It consists of several parts like diet, increased physical activity, lifestyle changes, drug therapy and surgery. However, obesity treatment is very often a failure, mostly because of discouraging long-term results and the necessity of intensive patient's involvement in the therapy. For many patients and doctors weight-decreasing agents look promising. The groups of anti-obesity drugs are presented in the article, with special reference to serotoninergic agents and intestinal lipase inhibitors. The prospects for new anti-obesity agents are discussed. Nevertheless, despite intensive research on obesity, we are still waiting for the development of an effective and safe drugs helping lose weight.
PubMed, Feb 24, 2001
Abnormalities of glucose metabolism are a common feature of acromegaly. Overt diabetes mellitus d... more Abnormalities of glucose metabolism are a common feature of acromegaly. Overt diabetes mellitus develops in about 10-15% of patients. We present an unusual complication of acromegaly: a 37-year old man with a 2-year history of acromegaly developed diabetic ketoacidosis 3 weeks after transsphenoidal adenomectomy. No specific cause for this sudden metabolic derangement could be demonstrated. Insulin need was very high in the first days after the onset of ketoacidosis, but was considerably reduced after initiation of treatment with octreotide and after successful re-operation.
PubMed, Sep 1, 2001
Recent epidemiologic studies show increasing "epidemic" of diabetes mellitus throughout the world... more Recent epidemiologic studies show increasing "epidemic" of diabetes mellitus throughout the world. Reliable data on diabetes prevalence in Poland are scarce. Therefore Polish Ministry of Health initiated a programme aiming at gathering substantial amount of epidemiologic data on the prevalence of diabetes and other metabolic disorders. The aim of the present study was to evaluate the prevalence of diabetes, obesity and lipid disorders in a well-defined urban population aged 35 and over. The study subjects were 6000 randomly chosen inhabitants of the Central District of Lodz. All were invitated to participate in the study by mail. Every participant underwent full medical examination, with body mass index (BMI) calculation, and blood pressure as well as waist-to-hip ratio measurements. Serum total, LDL and HDL cholesterol and triglycerides were assessed. In non-diabetes subjects oral glucose tolerance test (75 g) (OGTT) according to WHO protocol was performed unless their fasting capillary blood glucose exceeded 8 mmol/l. In selected subjects serum samples were stored for future insulin and C-peptide assays. 2018 persons took part in the study (response rate 33.6%), including 1217 (60.3%) women and 801 men (39.7%), mean age 58.2 years. 179 (8.9%) persons claimed to have been diagnosed with diabetes previously (8.9%). OGTT was performed in 1574 subjects. Impaired glucose tolerance (IGT) was found in 342 (17.0%), and diabetes in 138 (6.8%) subjects. Total diabetes prevalence reached therefore 15.7%. Excessive body weight (BMI > or = 25 kg/m2) was noted in 806 (39.9%), and obesity (BMI > or = 30 kg/m2) in 626 (31.0%) persons. Total cholesterol > 5.2 mmol/l was observed in 1170 (58.0%), LDL-cholesterol > 3.5 mmol/l in 734 (36.4%), cholesterol HDL < 0.9 mmol/l in 953 (47.2%), and triglycerides > 1.7 mmol/l in 1392 osób (69.0%) subjects. In conclusion, high prevalence of known and unknown diabetes together with other metabolic disorders is strikingly high in adult urban population, which in all may require effective implementation of specific nationwide prevention programmes.
Kardiologia Polska, Feb 17, 2014
Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine, Sep 1, 2005
People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thr... more People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thrombo-vascular complications than non-diabetics and it is recommended that they should use acetylsalicylic acid (ASA) as anitiplatelet agent regularly. The aim of this study was to examine current physician counseling about ASA therapy and the use of ASA by Polish patients with diabetes. The study involved 464 randomly selected Caucasian diabetic individuals, mainly with type 2 (&amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;98%), who were asked to complete a questionnaire consisting of 16 questions while visiting out-patient medical centres for periodical examination or during hospitalization. We collected data on the prevalence of cardiovascular disease (CVD), frequency of risk factors among diabetic patients and on ASA physician counseling, and on the rate of regular ASA users among the patients. The most self-reported conditions were angina pectoris or prior myocardial infarction (63,6%). Current cigarette smoking was declared by 7,1% of the patients, elevated serum cholesterol levels by 58%, and hypertension by 62,9%. Majority of the patients were overweight, and family history of coronary artery disease (CAD) was reported by 30,2% of the patients. ASA was taken by 67,2% of all the patients and 72,1% of them had taken ASA regularly. The highest percentage (&amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;80%) of regular ASA users was found among diabetic patients with CAD. A minority of the patients who reported stroke (43,9%) or claudication (15,8%) were taking ASA regularly. Number of the patients (32,8%) with CVD risk factor(s) but without diagnosed CVD did not use ASA at all. The majority of the patients (78%) were counseled by their physicians why they should use ASA regularly. the number of regular users of ASA among diabetic patients in Poland with CVD others than CAD or among patients with at least two CAD risk factors is still unsatisfactory. Therefore, while it seems that there is a remarkable growing of ASA therapy world-wide more effort is needed to make this practice a standard of multifactorial, intensive diabetes treatment. Our results also suggest the need for more aggressive education of both doctors and patients.
Diabetes Research and Clinical Practice, Sep 1, 2000
We measured serum levels of free leptin, bound leptin, and soluble leptin receptor by specific RI... more We measured serum levels of free leptin, bound leptin, and soluble leptin receptor by specific RIA methods in 20 normal and 19 insulin-dependent diabetes mellitus subjects at 20 and 30 weeks gestation and postpartum, and analyzed the data using hierarchical statistical models. Total leptin levels rise from 20-30 weeks gestation (688 +/- 58 to 785 +/- 62 pmol/L, mean +/- SEM; P = 0.009). There is a significant postpartum fall to 445 +/- 47 pmol/L (P &amp;amp;amp;amp;lt; 0.001). This rise is caused by the rise in the bound leptin levels, as there is no significant change in free leptin levels between 20 and 30 weeks (P = 0.17). There is a significant postpartum fall in free leptin levels (P &amp;amp;amp;amp;lt; 0.001). Insulin requirements rise in the third trimester, but despite this there was no significant difference in free or bound leptin levels between the normal and diabetic subjects at any stage [free leptin, 223 +/- 35 and 266 +/- 24, 237 +/- 45 and 223 +/- 27, and 109 +/- 16 and 104 +/- 24 (P = 0.34); bound leptin, 410 +/- 73 and 428 +/- 54, 501 +/- 78 and 562 +/- 71, and 330 +/- 47 and 271 +/- 46 (P = 0.84); for normals and diabetics at 20 and 30 weeks gestation and postpartum, respectively]. Diabetic subjects, however, had significantly higher soluble leptin receptor levels at all stages (P &amp;amp;amp;amp;lt; 0.001), which rose further in the third trimester from 3742 +/- 268 (mean +/- SEM) to 4134 +/- 239 pmol/L, whereas in the normal group there was a fall from 3149 +/- 169 to 2712 +/- 123 (P = 0.05). There is a linear relationship between the soluble leptin receptor levels and the body mass index in the diabetic group only. We conclude that there is no significant difference in free or bound leptin levels between the normal and insulin-dependent diabetic subjects either during pregnancy or postpartum, but female insulin-dependent diabetic subjects have significantly higher soluble leptin receptor levels. We speculate that high soluble leptin receptor levels might be implicated in the development of the leptin resistance in this group.
Polskie Archiwum Medycyny Wewnętrznej, 1976
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2000
Most of type 2. diabetic patients require medication for several concomitant diseases, most impor... more Most of type 2. diabetic patients require medication for several concomitant diseases, most important being, hypertension, ischaemic heart disease, heart failure, dyslipidaemias, obesity. Thus the risk of drug interactions is important, particularly in elderly patients. Oral antidiabetic drugs include hypoglycaemic agents (sulphonylureas, meglitenides) and biguanides (metformin), alpha-glucosidase inhibitors, tiazolinidediones. Drug interactions with antihyperglycaemic agents can be divided into pharmacokinetic and pharmacodynamic interactions. Numerous drugs due to interactions enhance hypoglycaemic action of sulphonylureas, thus increase the risk of hypoglycaemia. Several drugs may cause impairment of glycaemic control through various mechanisms in diabetic patients treated with oral antidiabetic drugs. Currently the most controversial problem is safety of combination therapy with sulphonylurea and metformin, as several observations indicated that it can increase mortality from ca...
Polski tygodnik lekarski (Warsaw, Poland : 1960), Jan 9, 1983
Diabetes Research and Clinical Practice, 2000
Blood Coagulation & Fibrinolysis, 2006
The effect of chronic hyperglycaemia on blood platelet response to acetylsalicylic acid was studi... more The effect of chronic hyperglycaemia on blood platelet response to acetylsalicylic acid was studied in rats with experimental diabetes. Platelet aggregation was determined in non-diabetic and streptozotocin-diabetic rats treated orally with 4 or 40 mg aspirin (ASA)/kg per day (for 8 weeks from the eighth day of diabetes) using whole blood impedance aggregometry with arachidonic acid or ADP as platelet agonists. The dose-dependent effect of ASA &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;therapy&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; on ADP-agonized platelets was significant only in non-diabetic animals, while in diabetic rats both doses were ineffective in reducing ADP-stimulated platelet aggregation. ASA-mediated increased acetylation of platelet proteins favoured reduced platelet aggregation and slower platelet disaggregation (Pr &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.025 or less). Interestingly, however, the occupation of platelet protein-free amino groups was significantly higher in control rats compared with diabetic rats (P &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001), pointing out that proteins of platelets in non-diabetic animals were more vulnerable for the ASA-induced acetylation. We conclude that chronic hyperglycaemia interferes with preventive effects of ASA on platelet reactivity. Our data validate the suggestion that the relationship between aspirin ineffectiveness and poor metabolic control, first revealed in humans, concerns also other animals&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; platelets and holds regardless of the model or type of diabetes.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 2008
Acta Anaesthesiologica Scandinavica, 2009
Diabetologia Praktyczna, 2017
Reports of Practical Oncology & Radiotherapy, 2003
Diabetes Care, Dec 1, 1999
R e f e re nc e s 1. Giugliano D, Ceriello A: Oxidative stre s s and diabetic vascular complicati... more R e f e re nc e s 1. Giugliano D, Ceriello A: Oxidative stre s s and diabetic vascular complications. D i abetes Care 19:257-267, 1996 2. U.K. Prospective Diabetes Study Gro u p : Intensive blood-glucose control with s u l p h o n y l u reas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Blood, Nov 16, 2004
Imatinib (STI571) is a 2-phenylaminopyrimidine derivative used mostly in the treatment of chronic... more Imatinib (STI571) is a 2-phenylaminopyrimidine derivative used mostly in the treatment of chronic myeloid leukaemia. It targets the BCR/ABL oncogenic tyrosine kinase, inhibiting its activity. Using the alkaline comet assay we showed that STI571 at concentrations ranging from 0.2 to 2 M induced DNA damage in human leukemic K562 and BV173 cells expressing the BCR/ABL oncogene, whereas it had no effect in normal human lymphocytes and leukemic CCRF-CEM cells without the expression of BCR/ABL. Imatinib did not induce DNA strand breaks in the direct interaction with DNA as examined by the circular plasmid relaxation assay. Because the extent of DNA damage observed in the neutral and pH 12.1 versions of the comet assay was much lesser than in the alkaline version, we concluded that the drug induced DNA alkali-labile sites rather than strand breaks. K562 cells were unable to repair H 2 O 2-induced DNA damage during a 120-min incubation, if they had been preincubated with STI571, whereas normal lymphocytes did so within 60 min. Pre-treatment of K562 cells with Vitamins A, C and E reduced the extent of DNA damage evoked by STI571. Similar results brought experiments with the nitrone spin traps POBN and PBN, suggesting that free radicals may be involved in the formation of DNA lesions induced by STI571 in K562 cells. These cells exposed to imatinib and treated with endonuclease III, formamidopyrimidine-DNA glycosylase and 3-methyladenine-DNA glycosylase II, the enzymes recognizing oxidized and alkylated bases, displayed greater extent of DNA damage than those not treated with these enzymes. Therefore, the mechanism of the anti-leukemic action of STI571 may involve not only the inhibition of BCR/ABL, but also DNA damage in the cells expressing this fusion protein. DNA damage induced by STI571 may follow from oxidative and alkylative base modifications.
Menopause Review/Przegląd Menopauzalny, May 11, 2009
Anaphylaxis is a severe, life-threatening systemic reaction of hypersensitivity occurring unexpec... more Anaphylaxis is a severe, life-threatening systemic reaction of hypersensitivity occurring unexpectedly in healthy individuals in response to an allergen. Anaphylactic shock combines anaphylaxis with coexisting hypotension. Aronia (Latin - Aronia melanocarpa, common name - black chokeberry) is a bush commonly grown in European countries. Its fruit is used in food industry for production of fruit products, including juices. Due to its antioxidative properties, aronia is recommended as a dietary supplement for people with arterial hypertension, diabetes and lipid metabolism disorders. We present a case of a 54 year old male patient with cardiovascular disease and type 2 diabetes, admitted with signs and symptoms of anaphylactic shock. The symptoms appeared directly after drinking aronia juice. Medical history revealed similar symptoms of alimentary hypersensitivity, requiring hospitalisation and intensive pharmacotherapy, occurred also following ingestion of highbush blueberries and raspberries. The presented case is the first case of anaphylactic shock following ingestion of aronia juice noted in the literature. Additionally, presence of some additional factors that could be responsible for development of hypersensitivity reaction is notable. It is suggested that the patient’s age, gender and presence of cardio-metabolic conditions, including type 2 diabetes, could play an important role.
PubMed, Nov 1, 2000
Obesity is one of the pathologies with ever-increasing prevalence in modern societies. Its occurr... more Obesity is one of the pathologies with ever-increasing prevalence in modern societies. Its occurrence is strongly associated with increased risk of developing diabetes mellitus, atherosclerosis, hypertension, stroke, heart and respiratory failure, breast, prostate and gut cancer, gall stones, arthropathy. Obesity is common in Polish population. Obesity treatment is difficult and frustrating. It consists of several parts like diet, increased physical activity, lifestyle changes, drug therapy and surgery. However, obesity treatment is very often a failure, mostly because of discouraging long-term results and the necessity of intensive patient's involvement in the therapy. For many patients and doctors weight-decreasing agents look promising. The groups of anti-obesity drugs are presented in the article, with special reference to serotoninergic agents and intestinal lipase inhibitors. The prospects for new anti-obesity agents are discussed. Nevertheless, despite intensive research on obesity, we are still waiting for the development of an effective and safe drugs helping lose weight.
PubMed, Feb 24, 2001
Abnormalities of glucose metabolism are a common feature of acromegaly. Overt diabetes mellitus d... more Abnormalities of glucose metabolism are a common feature of acromegaly. Overt diabetes mellitus develops in about 10-15% of patients. We present an unusual complication of acromegaly: a 37-year old man with a 2-year history of acromegaly developed diabetic ketoacidosis 3 weeks after transsphenoidal adenomectomy. No specific cause for this sudden metabolic derangement could be demonstrated. Insulin need was very high in the first days after the onset of ketoacidosis, but was considerably reduced after initiation of treatment with octreotide and after successful re-operation.
PubMed, Sep 1, 2001
Recent epidemiologic studies show increasing "epidemic" of diabetes mellitus throughout the world... more Recent epidemiologic studies show increasing "epidemic" of diabetes mellitus throughout the world. Reliable data on diabetes prevalence in Poland are scarce. Therefore Polish Ministry of Health initiated a programme aiming at gathering substantial amount of epidemiologic data on the prevalence of diabetes and other metabolic disorders. The aim of the present study was to evaluate the prevalence of diabetes, obesity and lipid disorders in a well-defined urban population aged 35 and over. The study subjects were 6000 randomly chosen inhabitants of the Central District of Lodz. All were invitated to participate in the study by mail. Every participant underwent full medical examination, with body mass index (BMI) calculation, and blood pressure as well as waist-to-hip ratio measurements. Serum total, LDL and HDL cholesterol and triglycerides were assessed. In non-diabetes subjects oral glucose tolerance test (75 g) (OGTT) according to WHO protocol was performed unless their fasting capillary blood glucose exceeded 8 mmol/l. In selected subjects serum samples were stored for future insulin and C-peptide assays. 2018 persons took part in the study (response rate 33.6%), including 1217 (60.3%) women and 801 men (39.7%), mean age 58.2 years. 179 (8.9%) persons claimed to have been diagnosed with diabetes previously (8.9%). OGTT was performed in 1574 subjects. Impaired glucose tolerance (IGT) was found in 342 (17.0%), and diabetes in 138 (6.8%) subjects. Total diabetes prevalence reached therefore 15.7%. Excessive body weight (BMI > or = 25 kg/m2) was noted in 806 (39.9%), and obesity (BMI > or = 30 kg/m2) in 626 (31.0%) persons. Total cholesterol > 5.2 mmol/l was observed in 1170 (58.0%), LDL-cholesterol > 3.5 mmol/l in 734 (36.4%), cholesterol HDL < 0.9 mmol/l in 953 (47.2%), and triglycerides > 1.7 mmol/l in 1392 osób (69.0%) subjects. In conclusion, high prevalence of known and unknown diabetes together with other metabolic disorders is strikingly high in adult urban population, which in all may require effective implementation of specific nationwide prevention programmes.
Kardiologia Polska, Feb 17, 2014
Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine, Sep 1, 2005
People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thr... more People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thrombo-vascular complications than non-diabetics and it is recommended that they should use acetylsalicylic acid (ASA) as anitiplatelet agent regularly. The aim of this study was to examine current physician counseling about ASA therapy and the use of ASA by Polish patients with diabetes. The study involved 464 randomly selected Caucasian diabetic individuals, mainly with type 2 (&amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;98%), who were asked to complete a questionnaire consisting of 16 questions while visiting out-patient medical centres for periodical examination or during hospitalization. We collected data on the prevalence of cardiovascular disease (CVD), frequency of risk factors among diabetic patients and on ASA physician counseling, and on the rate of regular ASA users among the patients. The most self-reported conditions were angina pectoris or prior myocardial infarction (63,6%). Current cigarette smoking was declared by 7,1% of the patients, elevated serum cholesterol levels by 58%, and hypertension by 62,9%. Majority of the patients were overweight, and family history of coronary artery disease (CAD) was reported by 30,2% of the patients. ASA was taken by 67,2% of all the patients and 72,1% of them had taken ASA regularly. The highest percentage (&amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;80%) of regular ASA users was found among diabetic patients with CAD. A minority of the patients who reported stroke (43,9%) or claudication (15,8%) were taking ASA regularly. Number of the patients (32,8%) with CVD risk factor(s) but without diagnosed CVD did not use ASA at all. The majority of the patients (78%) were counseled by their physicians why they should use ASA regularly. the number of regular users of ASA among diabetic patients in Poland with CVD others than CAD or among patients with at least two CAD risk factors is still unsatisfactory. Therefore, while it seems that there is a remarkable growing of ASA therapy world-wide more effort is needed to make this practice a standard of multifactorial, intensive diabetes treatment. Our results also suggest the need for more aggressive education of both doctors and patients.
Diabetes Research and Clinical Practice, Sep 1, 2000
We measured serum levels of free leptin, bound leptin, and soluble leptin receptor by specific RI... more We measured serum levels of free leptin, bound leptin, and soluble leptin receptor by specific RIA methods in 20 normal and 19 insulin-dependent diabetes mellitus subjects at 20 and 30 weeks gestation and postpartum, and analyzed the data using hierarchical statistical models. Total leptin levels rise from 20-30 weeks gestation (688 +/- 58 to 785 +/- 62 pmol/L, mean +/- SEM; P = 0.009). There is a significant postpartum fall to 445 +/- 47 pmol/L (P &amp;amp;amp;amp;lt; 0.001). This rise is caused by the rise in the bound leptin levels, as there is no significant change in free leptin levels between 20 and 30 weeks (P = 0.17). There is a significant postpartum fall in free leptin levels (P &amp;amp;amp;amp;lt; 0.001). Insulin requirements rise in the third trimester, but despite this there was no significant difference in free or bound leptin levels between the normal and diabetic subjects at any stage [free leptin, 223 +/- 35 and 266 +/- 24, 237 +/- 45 and 223 +/- 27, and 109 +/- 16 and 104 +/- 24 (P = 0.34); bound leptin, 410 +/- 73 and 428 +/- 54, 501 +/- 78 and 562 +/- 71, and 330 +/- 47 and 271 +/- 46 (P = 0.84); for normals and diabetics at 20 and 30 weeks gestation and postpartum, respectively]. Diabetic subjects, however, had significantly higher soluble leptin receptor levels at all stages (P &amp;amp;amp;amp;lt; 0.001), which rose further in the third trimester from 3742 +/- 268 (mean +/- SEM) to 4134 +/- 239 pmol/L, whereas in the normal group there was a fall from 3149 +/- 169 to 2712 +/- 123 (P = 0.05). There is a linear relationship between the soluble leptin receptor levels and the body mass index in the diabetic group only. We conclude that there is no significant difference in free or bound leptin levels between the normal and insulin-dependent diabetic subjects either during pregnancy or postpartum, but female insulin-dependent diabetic subjects have significantly higher soluble leptin receptor levels. We speculate that high soluble leptin receptor levels might be implicated in the development of the leptin resistance in this group.
Polskie Archiwum Medycyny Wewnętrznej, 1976
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2000
Most of type 2. diabetic patients require medication for several concomitant diseases, most impor... more Most of type 2. diabetic patients require medication for several concomitant diseases, most important being, hypertension, ischaemic heart disease, heart failure, dyslipidaemias, obesity. Thus the risk of drug interactions is important, particularly in elderly patients. Oral antidiabetic drugs include hypoglycaemic agents (sulphonylureas, meglitenides) and biguanides (metformin), alpha-glucosidase inhibitors, tiazolinidediones. Drug interactions with antihyperglycaemic agents can be divided into pharmacokinetic and pharmacodynamic interactions. Numerous drugs due to interactions enhance hypoglycaemic action of sulphonylureas, thus increase the risk of hypoglycaemia. Several drugs may cause impairment of glycaemic control through various mechanisms in diabetic patients treated with oral antidiabetic drugs. Currently the most controversial problem is safety of combination therapy with sulphonylurea and metformin, as several observations indicated that it can increase mortality from ca...
Polski tygodnik lekarski (Warsaw, Poland : 1960), Jan 9, 1983
Diabetes Research and Clinical Practice, 2000
Blood Coagulation & Fibrinolysis, 2006
The effect of chronic hyperglycaemia on blood platelet response to acetylsalicylic acid was studi... more The effect of chronic hyperglycaemia on blood platelet response to acetylsalicylic acid was studied in rats with experimental diabetes. Platelet aggregation was determined in non-diabetic and streptozotocin-diabetic rats treated orally with 4 or 40 mg aspirin (ASA)/kg per day (for 8 weeks from the eighth day of diabetes) using whole blood impedance aggregometry with arachidonic acid or ADP as platelet agonists. The dose-dependent effect of ASA &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;therapy&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; on ADP-agonized platelets was significant only in non-diabetic animals, while in diabetic rats both doses were ineffective in reducing ADP-stimulated platelet aggregation. ASA-mediated increased acetylation of platelet proteins favoured reduced platelet aggregation and slower platelet disaggregation (Pr &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.025 or less). Interestingly, however, the occupation of platelet protein-free amino groups was significantly higher in control rats compared with diabetic rats (P &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001), pointing out that proteins of platelets in non-diabetic animals were more vulnerable for the ASA-induced acetylation. We conclude that chronic hyperglycaemia interferes with preventive effects of ASA on platelet reactivity. Our data validate the suggestion that the relationship between aspirin ineffectiveness and poor metabolic control, first revealed in humans, concerns also other animals&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; platelets and holds regardless of the model or type of diabetes.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 2008
Acta Anaesthesiologica Scandinavica, 2009
Diabetologia Praktyczna, 2017
Reports of Practical Oncology & Radiotherapy, 2003
Diabetes Care, Dec 1, 1999
R e f e re nc e s 1. Giugliano D, Ceriello A: Oxidative stre s s and diabetic vascular complicati... more R e f e re nc e s 1. Giugliano D, Ceriello A: Oxidative stre s s and diabetic vascular complications. D i abetes Care 19:257-267, 1996 2. U.K. Prospective Diabetes Study Gro u p : Intensive blood-glucose control with s u l p h o n y l u reas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Blood, Nov 16, 2004
Imatinib (STI571) is a 2-phenylaminopyrimidine derivative used mostly in the treatment of chronic... more Imatinib (STI571) is a 2-phenylaminopyrimidine derivative used mostly in the treatment of chronic myeloid leukaemia. It targets the BCR/ABL oncogenic tyrosine kinase, inhibiting its activity. Using the alkaline comet assay we showed that STI571 at concentrations ranging from 0.2 to 2 M induced DNA damage in human leukemic K562 and BV173 cells expressing the BCR/ABL oncogene, whereas it had no effect in normal human lymphocytes and leukemic CCRF-CEM cells without the expression of BCR/ABL. Imatinib did not induce DNA strand breaks in the direct interaction with DNA as examined by the circular plasmid relaxation assay. Because the extent of DNA damage observed in the neutral and pH 12.1 versions of the comet assay was much lesser than in the alkaline version, we concluded that the drug induced DNA alkali-labile sites rather than strand breaks. K562 cells were unable to repair H 2 O 2-induced DNA damage during a 120-min incubation, if they had been preincubated with STI571, whereas normal lymphocytes did so within 60 min. Pre-treatment of K562 cells with Vitamins A, C and E reduced the extent of DNA damage evoked by STI571. Similar results brought experiments with the nitrone spin traps POBN and PBN, suggesting that free radicals may be involved in the formation of DNA lesions induced by STI571 in K562 cells. These cells exposed to imatinib and treated with endonuclease III, formamidopyrimidine-DNA glycosylase and 3-methyladenine-DNA glycosylase II, the enzymes recognizing oxidized and alkylated bases, displayed greater extent of DNA damage than those not treated with these enzymes. Therefore, the mechanism of the anti-leukemic action of STI571 may involve not only the inhibition of BCR/ABL, but also DNA damage in the cells expressing this fusion protein. DNA damage induced by STI571 may follow from oxidative and alkylative base modifications.